459 results on '"Mohr, Peter"'
Search Results
2. Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma
3. Hybrid-3D robotic suite in spine and trauma surgery - experiences in 210 patients
4. Early versus late response to PD-1-based immunotherapy in metastatic melanoma
5. Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
6. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
7. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
8. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
9. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
10. Predicting compliance: Leveraging chat data for supervised classification in experimental research
11. Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
12. LASSO logistic regression reveals a mixed MiRNA and serum-marker classifier for prediction of immunotherapy response in liquid biopsies of melanoma patients
13. Electronic patient-reported outcomes, fever management, and symptom prediction among patients with BRAF V600 mutant stage III–IV melanoma: The Kaiku Health platform
14. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
15. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
16. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors
17. Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
18. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
19. Cross sections at sub-Coulomb energies: full optical model vs.\ barrier transmission for $^{40}$Ca + $\alpha$
20. Characterisation and outcome of RAC1 mutated melanoma
21. 2022 taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales
22. German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023
23. Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
24. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
25. Clinical determinants of long-term survival in metastatic uveal melanoma
26. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
27. Uncertainty of the astrophysical $^{17,18}$O($\alpha$,n)$^{20,21}$Ne reaction rates and the applicability of the statistical model for nuclei with $A \lesssim 20$
28. Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg.
29. Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.
30. Development of a new real-time PCR for the detection of pilchard orthomyxovirus (POMV) in apparently healthy fish
31. Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits
32. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
33. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
34. Eating to dare - Nutrition impacts human risky decision and related brain function
35. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
36. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
37. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
38. Total reaction cross section of light stable and exotic nuclei on lead at energies around the Coulomb barrier.
39. Dr Graham Steell and monaural stethoscopes: Cardiology before the ECG.
40. BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist.
41. Comparative transcriptome analysis of pilchard orthomyxovirus (POMV) and infectious salmon anaemia virus (ISAV)
42. Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors
43. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
44. A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries
45. Constraining nucleosythesis in neutrino-driven winds using the impact of (α, xn) reaction rates
46. TaqMan real-time and conventional nested PCR tests specific to yellow head virus genotype 7 (YHV7) identified in giant tiger shrimp in Australia
47. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma
48. Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events.
49. Telefonische Verlaufskontrolle nach ambulanten nagelchirurgischen Eingriffen – eine retrospektive Analyse.
50. Telephone follow‐up after outpatient nail surgery – a retrospective analysis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.